Literature DB >> 22086477

[Historical and current pathophysiological concepts of stress (Tako-Tsubo) cardiomyopathy].

S Szardien1, H Möllmann, A Elsässer, C W Hamm, H M Nef.   

Abstract

Tako-Tsubo cardiomyopathy (TTC), also referred to as stress cardiomyopathy (SCM), was first described in the 1990s and is characterized by transient left ventricular dysfunction. Its incidence represents 1-2% of all acute coronary syndromes (ACS). In most cases extreme emotional or physical stress precedes this syndrome. The majority of patients affected are postmenopausal women. Since its first description, various hypotheses regarding the pathophysiology of TTC have been discussed. From a historical perspective, coronary vasospasm has often been proposed as a possible cause of this disorder. However, reviews from numerous registries were able to demonstrate that coronary vasospasm plays only a minor role in the pathogenesis of TTC. Several groups showed disturbances in myocardial microcirculation and energy metabolism in the acute phase of TTC. Nevertheless, with regard to the data currently available, it cannot be differentiated whether these changes are the cause or rather the result of TTC. However, recent concepts include an excessive catecholamine overload and morphological changes which are unequivocally documented in TTC. The relation between elevated catecholamine levels and myocardial dysfunction analogous to TTC could be confirmed in animal experiments.In summary, it can be assumed that TTC is caused by an excessive cardiotoxic release of catecholamines. Ventricular dysfunction can be explained by increased numbers of β-adrenergic receptors in the apex, leading to greater vulnerability to catecholamine overload. Individual anatomical differences in the sympathoadrenergic system and distribution from β-adrenergic receptors are presumably responsible for the interindividual occurrence of wall motion abnormalities in TTC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22086477     DOI: 10.1007/s00059-011-3446-3

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  48 in total

1.  Transient left ventricular apical ballooning in a community hospital in Germany.

Authors:  Klaus Hertting; Korff Krause; Tobias Härle; Sigrid Boczor; Jacobus Reimers; Karl-Heinz Kuck
Journal:  Int J Cardiol       Date:  2005-12-01       Impact factor: 4.164

2.  Tako-Tsubo cardiomyopathy: intraindividual structural analysis in the acute phase and after functional recovery.

Authors:  Holger M Nef; Helge Möllmann; Sawa Kostin; Christian Troidl; Sandra Voss; Michael Weber; Thorsten Dill; Andreas Rolf; Roland Brandt; Christian W Hamm; Albrecht Elsässer
Journal:  Eur Heart J       Date:  2007-03-29       Impact factor: 29.983

3.  Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop.

Authors:  R A Kloner; R Bolli; E Marban; L Reinlib; E Braunwald
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

4.  Remodeling of extracellular matrix protein, collagen by beta-adrenoceptor stimulation and denervation in mouse gastrocnemius muscle.

Authors:  Rakesh Kumar; Sushma Sharma
Journal:  J Physiol Sci       Date:  2006-02       Impact factor: 2.781

5.  Increased responsiveness of left ventricular apical myocardium to adrenergic stimuli.

Authors:  H Mori; S Ishikawa; S Kojima; J Hayashi; Y Watanabe; J I Hoffman; H Okino
Journal:  Cardiovasc Res       Date:  1993-02       Impact factor: 10.787

6.  Neurohumoral features of myocardial stunning due to sudden emotional stress.

Authors:  Ilan S Wittstein; David R Thiemann; Joao A C Lima; Kenneth L Baughman; Steven P Schulman; Gary Gerstenblith; Katherine C Wu; Jeffrey J Rade; Trinity J Bivalacqua; Hunter C Champion
Journal:  N Engl J Med       Date:  2005-02-10       Impact factor: 91.245

Review 7.  Emotional stress-induced Tako-tsubo cardiomyopathy: animal model and molecular mechanism.

Authors:  Takashi Ueyama
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

Review 8.  Stress (Takotsubo) cardiomyopathy--a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning.

Authors:  Alexander R Lyon; Paul S C Rees; Sanjay Prasad; Philip A Poole-Wilson; Sian E Harding
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-01

9.  Connective tissue growth factor--a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats.

Authors:  Mohammed Shakil Ahmed; Erik Øie; Leif Erik Vinge; Arne Yndestad; Geir Øystein Andersen; Yvonne Andersson; Toril Attramadal; Håvard Attramadal
Journal:  J Mol Cell Cardiol       Date:  2004-03       Impact factor: 5.000

10.  Apical regional wall motion abnormalities reminiscent to Tako-Tsubo cardiomyopathy following consumption of psychoactive fungi.

Authors:  Holger M Nef; Helge Möllmann; Pirmin Hilpert; Nicola Krause; Christian Troidl; Michael Weber; Andreas Rolf; Thorsten Dill; Christian Hamm; A Elsässer
Journal:  Int J Cardiol       Date:  2008-04-02       Impact factor: 4.164

View more
  5 in total

1.  [Tako-Tsubo cardiomyopathy--what do, what don't we know?].

Authors:  C Burgdorf; R Erbel
Journal:  Herz       Date:  2010-06       Impact factor: 1.443

2.  [Levosimendan for septic shock with takotsubo cardiomyopathy].

Authors:  C-N Schlürmann; J Reinöhl; J Kalbhenn
Journal:  Anaesthesist       Date:  2016-01       Impact factor: 1.041

3.  [Patient care in the acute phase of stress induced cardiomyopathy (Tako-Tsubo cardiomyopathy)--and thereafter?].

Authors:  V Kurowski; P W Radke; H Schunkert; C Burgdorf
Journal:  Herz       Date:  2010-06       Impact factor: 1.443

4.  Targeting of the Akt/PKB kinase to the actin skeleton.

Authors:  V Cenni; A Sirri; M Riccio; G Lattanzi; S Santi; A de Pol; N M Maraldi; S Marmiroli
Journal:  Cell Mol Life Sci       Date:  2003-12       Impact factor: 9.261

Review 5.  Novel aspects and new roles for the serine protease plasmin.

Authors:  T Syrovets; Th Simmet
Journal:  Cell Mol Life Sci       Date:  2004-04       Impact factor: 9.261

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.